請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89715
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 吳亞克 | zh_TW |
dc.contributor.advisor | Andrey Akhmetzhanov | en |
dc.contributor.author | 路易吉 | zh_TW |
dc.contributor.author | Luis Jose Ponce | en |
dc.date.accessioned | 2023-09-18T16:07:17Z | - |
dc.date.available | 2023-11-09 | - |
dc.date.copyright | 2023-09-18 | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2023-06-28 | - |
dc.identifier.citation | [1] “Update: Multistate Outbreak of Monkeypox --- Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003.” Accessed: Apr. 27, 2023. [Online]. Available: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5227a5.htm
[2] I. D. Ladnyj, P. Ziegler, and E. Kima, “A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo,” Bull. World Health Organ., vol. 46, no. 5, pp. 593–597, 1972. [3] “Mpox in the U.S.,” Centers for Disease Control and Prevention, Jan. 06, 2023. https://www.cdc.gov/poxvirus/mpox/index.html (accessed Apr. 27, 2023). [4] Z. Ježek and F. Fenner, Human monkeypox. in Monographs in virology, no. vol. 17. Basel ; New York: Karger, 1988. [5] A. Yinka-Ogunleye et al., “Reemergence of Human Monkeypox in Nigeria, 2017,” Emerg. Infect. Dis., vol. 24, no. 6, pp. 1149–1151, Jun. 2018, doi: 10.3201/eid2406.180017. [6] P. E. M. FINE, Z. JEZEK, B. GRAB, and H. DIXON, “The Transmission Potential of Monkeypox Virus in Human Populations,” Int. J. Epidemiol., vol. 17, no. 3, pp. 643–650, Sep. 1988, doi: 10.1093/ije/17.3.643. [7] “WHO Director-General declares the ongoing monkeypox outbreak a Public Health Emergency of International Concern.” https://www.who.int/europe/news/item/23-07-2022-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-event-of-international-concern (accessed May 27, 2023). [8] “WHO recommends new name for monkeypox disease.” https://www.who.int/news/item/28-11-2022-who-recommends-new-name-for-monkeypox-disease (accessed Apr. 27, 2023). [9] J. G. Breman, “Monkeypox: an Emerging Infection for Humans?,” in Emerging Infections 4, John Wiley & Sons, Ltd, 2000, pp. 45–67. doi: 10.1128/9781555816971.ch5. [10] M. S. Maldonado et al., “Epidemiologic characteristics and clinical features of patients with monkeypox virus infection from a hospital in Peru between July and September 2022,” Int. J. Infect. Dis., vol. 129, pp. 175–180, Apr. 2023, doi: 10.1016/j.ijid.2023.01.045. [11] “2022-23 Mpox (Monkeypox) Outbreak: Global Trends.” https://worldhealthorg.shinyapps.io/mpx_global/ (accessed Apr. 27, 2023). [12] M. G. Reynolds et al., “Clinical Manifestations of Human Monkeypox Influenced by Route of Infection,” J. Infect. Dis., vol. 194, no. 6, pp. 773–780, Sep. 2006, doi: 10.1086/505880. [13] A. P. Riser et al., “Epidemiologic and Clinical Features of Mpox-Associated Deaths — United States, May 10, 2022–March 7, 2023,” MMWR Morb. Mortal. Wkly. Rep., vol. 72, no. 15, pp. 404–410, Apr. 2023, doi: 10.15585/mmwr.mm7215a5. [14] “Joint ECDC-WHO Regional Office for Europe Mpox Surveillance Bulletin.” https://monkeypoxreport.ecdc.europa.eu/ (accessed Apr. 27, 2023). [15] “Israel confirms first communal spread of monkeypox | The Times of Israel.” https://www.timesofisrael.com/israel-confirms-first-communal-spread-of-monkeypox/ (accessed Apr. 27, 2023). [16] Md. S. Islam, A. M. M. T. Rahman, and Md. T. Rahman, “Mpox is still being neglected in South-East Asia region: Possible challenges to control,” New Microbes New Infect., vol. 52, p. 101109, Mar. 2023, doi: 10.1016/j.nmni.2023.101109. [17] “Mpox Cases Top 100 in Japan, 10 New Patients Confirmed,” PHARMA JAPAN. https://pj.jiho.jp/article/248661 (accessed Apr. 27, 2023). [18] Y. Wolff Sagy et al., “Real-world effectiveness of a single dose of mpox vaccine in males,” Nat. Med., vol. 29, no. 3, pp. 748–752, Mar. 2023, doi: 10.1038/s41591-023-02229-3. [19] “Monkeypox outbreak: India to screen arrival for virus signs, isolate sick patients; details here | India News | Zee News.” https://zeenews.india.com/india/monkeypox-outbreak-india-to-screen-arrival-for-virus-signs-isolate-sick-patients-details-here-2465745.html (accessed Apr. 27, 2023). [20] “No monkeypox cases detected in Saudi Arabia, health ministry says.” https://www.arabnews.com/node/2087001/saudi-arabia (accessed Apr. 27, 2023). [21] M. J. Page et al., “The PRISMA 2020 statement: an updated guideline for reporting systematic reviews,” BMJ, p. n71, Mar. 2021, doi: 10.1136/bmj.n71. [22] M. Viedma-Martinez et al., “MPXV Transmission at a Tattoo Parlor,” N. Engl. J. Med., vol. 388, no. 1, pp. 92–94, Jan. 2023, doi: 10.1056/NEJMc2210823. [23] F. Miura et al., “Estimated incubation period for monkeypox cases confirmed in the Netherlands, May 2022,” Eurosurveillance, vol. 27, no. 24, Jun. 2022, doi: 10.2807/1560-7917.ES.2022.27.24.2200448. [24] E. J. Tarín-Vicente et al., “Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study,” The Lancet, vol. 400, no. 10353, pp. 661–669, Aug. 2022, doi: 10.1016/S0140-6736(22)01436-2. [25] Z. J. Madewell et al., “Serial Interval and Incubation Period Estimates of Monkeypox Virus Infection in 12 Jurisdictions, United States, May–August 2022 - Volume 29, Number 4—April 2023 - Emerging Infectious Diseases journal - CDC”, doi: 10.3201/eid2904.221622. [26] M. Harrer, Doing meta-analysis with R: a hands-on guide, First edition. Boca Raton: CRC Press, 2022. [27] R. DerSimonian and R. Kacker, “Random-effects model for meta-analysis of clinical trials: an update,” Contemp. Clin. Trials, vol. 28, no. 2, pp. 105–114, Feb. 2007, doi: 10.1016/j.cct.2006.04.004. [28] Stan Development Team, “Stan Modeling Language Users Guide and Reference Manual.” 2023. [Online]. Available: https://mc-stan.org [29] R Core Team, “R: A Language and Environment for Statistical Computing.” R Foundation for Statistical Computing, Vienna, Austria, 2023. [Online]. Available: https://ww.R-project.org/ [30] M. E. Halloran, M. Haber, I. M. Longini, and C. J. Struchiner, “Direct and Indirect Effects in Vaccine Efficacy and Effectiveness,” Am. J. Epidemiol., vol. 133, no. 4, pp. 323–331, Feb. 1991, doi: 10.1093/oxfordjournals.aje.a115884. [31] J. Peto et al., “Universal weekly testing as the UK COVID-19 lockdown exit strategy,” The Lancet, vol. 395, no. 10234, pp. 1420–1421, May 2020, doi: 10.1016/S0140-6736(20)30936-3. [32] J. P. Klein and M. L. Moeschberger, “Censoring and Truncation,” in Survival Analysis, in Statistics for Biology and Health. New York, NY: Springer New York, 2003, pp. 63–90. doi: 10.1007/0-387-21645-6_3. [33] A. Vehtari, A. Gelman, and J. Gabry, “Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC,” Stat. Comput., vol. 27, no. 5, pp. 1413–1432, Sep. 2017, doi: 10.1007/s11222-016-9696-4. [34] I. D. Ladnyj, P. Ziegler, and E. Kima, “A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo,” Bull. World Health Organ., vol. 46, no. 5, pp. 593–597, 1972. [35] J. C. Kile et al., “Article,” Arch. Pediatr. Adolesc. Med., vol. 159, no. 11, pp. 1022–1025, Nov. 2005, doi: 10.1001/archpedi.159.11.1022. [36] N. Erez et al., “Diagnosis of Imported Monkeypox, Israel, 2018 - Volume 25, Number 5—May 2019 - Emerging Infectious Diseases journal - CDC”, doi: 10.3201/eid2505.190076. [37] I. K. Damon, C. E. Roth, and V. Chowdhary, “Discovery of Monkeypox in Sudan,” N. Engl. J. Med., vol. 355, no. 9, pp. 962–963, Aug. 2006, doi: 10.1056/NEJMc060792. [38] R. H. Doshi et al., “Epidemiologic and Ecologic Investigations of Monkeypox, Likouala Department, Republic of the Congo, 2017 - Volume 25, Number 2—February 2019 - Emerging Infectious Diseases journal - CDC”, doi: 10.3201/eid2502.181222. [39] A. T. Fleischauer et al., “Evaluation of Human-to-Human Transmission of Monkeypox from Infected Patients to Health Care Workers,” Clin. Infect. Dis., vol. 40, no. 5, pp. 689–694, Mar. 2005, doi: 10.1086/427805. [40] “Exportation of Monkeypox Virus From the African Continent | The Journal of Infectious Diseases | Oxford Academic.” https://academic.oup.com/jid/article/225/8/1367/5901023?login=true (accessed Apr. 30, 2023). [41] L. D. Nolen et al., “Extended Human-to-Human Transmission during a Monkeypox Outbreak in the Democratic Republic of the Congo - Volume 22, Number 6—June 2016 - Emerging Infectious Diseases journal - CDC”, doi: 10.3201/eid2206.150579. [42] G. Hobson et al., “Family cluster of three cases of monkeypox imported from Nigeria to the United Kingdom, May 2021,” Eurosurveillance, vol. 26, no. 32, p. 2100745, Aug. 2021, doi: 10.2807/1560-7917.ES.2021.26.32.2100745. [43] Z. Jezek, I. Arita, M. Mutombo, C. Dunn, J. H. Nakano, and M. Szczeniowski, “Four generations of probable person-to-person transmission of human monkeypox,” Am. J. Epidemiol., vol. 123, no. 6, pp. 1004–1012, Jun. 1986, doi: 10.1093/oxfordjournals.aje.a114328. [44] S. O. Foster et al., “Human monkeypox,” Bull. World Health Organ., vol. 46, no. 5, pp. 569–576, 1972. [45] P. Formenty et al., “Human Monkeypox Outbreak Caused by Novel Virus Belonging to Congo Basin Clade, Sudan, 2005 - Volume 16, Number 10—October 2010 - Emerging Infectious Diseases journal - CDC”, doi: 10.3201/eid1610.100713. [46] M. Mutombo, Z. Jezek, I. Arita, and Z. Jezek, “HUMAN MONKEYPOX TRANSMITTED BY A CHIMPANZEE IN A TROPICAL RAIN-FOREST AREA OF ZAIRE,” The Lancet, vol. 321, no. 8327, pp. 735–737, Apr. 1983, doi: 10.1016/S0140-6736(83)92027-5. [47] A. Vaughan et al., “Human-to-Human Transmission of Monkeypox Virus, United Kingdom, October 2018 - Volume 26, Number 4—April 2020 - Emerging Infectious Diseases journal - CDC”, doi: 10.3201/eid2604.191164. [48] S. E. F. Yong et al., “Imported Monkeypox, Singapore - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC”, doi: 10.3201/eid2608.191387. [49] “Monkeypox - the United States of America.” https://www.who.int/emergencies/disease-outbreak-news/item/monkeypox---the-united-states-of-america (accessed Apr. 30, 2023). [50] “Monkeypox - United Kingdom of Great Britain and Northern Ireland ex Nigeria.” https://www.who.int/emergencies/disease-outbreak-news/item/monkeypox---united-kingdom-of-great-britain-and-northern-ireland-ex-nigeria (accessed Apr. 30, 2023). [51] G. Froeschl and P. K. Kayembe, “Pox-like lesions and haemorrhagic fever in two concurrent cases in the Central African Republic: case investigation and management in difficult circumstances,” Pan Afr. Med. J., vol. 22, no. 23, Art. no. 23, Oct. 2015, doi: 10.11604/pamj.2015.22.23.6620. [52] K. D. Reed et al., “The Detection of Monkeypox in Humans in the Western Hemisphere,” N. Engl. J. Med., vol. 350, no. 4, pp. 342–350, Jan. 2004, doi: 10.1056/NEJMoa032299. [53] T. Ward, R. Christie, R. S. Paton, F. Cumming, and C. E. Overton, “Transmission dynamics of monkeypox in the United Kingdom: contact tracing study,” BMJ, p. e073153, Nov. 2022, doi: 10.1136/bmj-2022-073153. [54] Z. Guo, S. Zhao, S. Sun, D. He, K. C. Chong, and E. K. Yeoh, “Estimation of the serial interval of monkeypox during the early outbreak in 2022,” J. Med. Virol., vol. 95, no. 1, p. e28248, 2023, doi: 10.1002/jmv.28248. | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89715 | - |
dc.description.abstract | 引言:Mpox(前稱為猴痘)是一種病毒性疾病,與天花屬於同一家族,其特徵為特殊的皮疹和發燒。Mpox的症狀從輕微到嚴重不等,可能持續數周,給患者帶來明顯的身體不適和情緒困擾。此外,由於需要專業護理和可能的併發症,Mpox對醫療系統造成相當的負擔。了解Mpox的傳播動力學和關鍵流行病學因素對於制定有效的控制措施,減輕該疾病對公共衛生的影響至關重要。本研究旨在評估2022年國際爆發前後Mpox病例的傳播動力學,重點是確定平均潛伏期。
方法:為達到研究目標,我們進行了對Mpox傳播事件的系統性回顧,提取了來自不同數據集的暴露和症狀發作日期。使用馬可夫鏈蒙特卡洛抽樣進行潛伏期分佈的估計。採用貝葉斯元分析方法比較並分析本研究和現有同行評審文獻中計算的潛伏期。 結果:該研究的發現顯示,合併平均潛伏期為7.80天,95%可信區間為6.98至8.61天。值得注意的是,在預2022年的水痘疫情和目前的全球疫情之間並未觀察到明顯的流行病學差異。分析還確定了所有後驗暴露至出疹期的95th、97.5th和99th百分位數分別為15.7、16.9和20.4天。 結論:根據研究結果,建議將隔離期限訂為21天。值得考慮的是,估計水痘暴露至出疹期間可能提供更多有價值的見解,因為與出疹不同,其他症狀可能不容易被辨認。該研究有助於了解水痘的傳播動態並為公共衛生措施提供有價值的資訊。 | zh_TW |
dc.description.abstract | Introduction: Mpox (formerly monkeypox) is a viral disease that belongs to the same family as smallpox and is characterized by a distinctive rash and fever. The symptoms of mpox can range from mild to severe and can persist for several weeks, leading to significant physical discomfort and emotional distress for affected individuals. Additionally, mpox poses a considerable burden on healthcare systems due to the need for specialized care and potential complications. Understanding the transmission dynamics and key epidemiological factors of mpox is crucial for developing effective control measures and reducing the impact of this disease on public health. This study aimed to assess the transmission dynamics of mpox cases before and after the 2022 international outbreak, focusing on determining the average incubation period.
Methods: To achieve the study objective, a systematic review of mpox transmission events was conducted, and exposure and symptom onset dates from different datasets were extracted. Estimations of incubation period distributions were performed using Markov Chain Monte Carlo sampling. A Bayesian meta-analysis approach was employed to compare and analyze incubation periods calculated in this study and in pre-existing peer-reviewed literature. Results: The findings of the study revealed a pooled mean incubation period of 7.80 days, with a 95% credible interval ranging from 6.98 to 8.61 days. Notably, no distinguishable epidemiological differences were observed between pre-2022 mpox outbreaks and the current global outbreak. The analysis also identified the 95th, 97.5th, and 99th percentiles of all the posterior exposure-to-rash onset draws as 15.7, 16.9, and 20.4 days, respectively. Conclusions: Based on the study's results, a recommended quarantine period of 21 days is suggested. It is worth considering that estimating the period between mpox exposure and rash onset may provide more informative insights, as other symptoms may not be as easily identifiable as a rash. The study contributes to the understanding of mpox transmission dynamics and provides valuable information for public health measures. | en |
dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2023-09-18T16:07:17Z No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2023-09-18T16:07:17Z (GMT). No. of bitstreams: 0 | en |
dc.description.tableofcontents | Acknowledgements ii
Abstract (Chinese) iii Abstract (English) iv 1 Introduction 1 1.1 History of Mpox Outbreaks 1 1.2 Clinical Characteristics of Mpox 2 1.3 Epidemiological Characteristics of Mpox 4 1.4 Current Events of Mpox 6 1.5 Public Health Responses to Mpox 8 1.6 Research Objectives 8 2 Methods 10 2.1 Systematic Review and Meta-Analysis 10 2.1.1 Search Strategy 10 2.1.2 Inclusion and Exclusion Criteria 10 2.1.3 Outcome Measures and Study Selection 11 2.1.4 Meta-Analysis 12 2.2 Data Descriptions and Preparation for Analysis 15 2.3 Statistical Analyses 17 2.3.1 Bayesian Statistics and Markov Chain Monte Carlo Sampling 18 2.3.2 Probability Distributions 19 2.3.3 Fitting the Data and Exposure-to-symptom onset Period Estimations 21 2.3.4 Model Assessment and Selection Through Likelihood Functions 22 2.3.5 Exposure-to-Rash or Symptom Onset Period 25 3 Results 27 3.1 PRISMA Systematic Review 27 3.2 Estimated Mean Exposure-to-Symptom Onset Periods and Model Assessments 28 3.2.1 Pre-2022 Data 28 3.2.2 Tarin-Vicente et al. Data 29 3.2.3 Viedma-Martinez et al. Data 30 3.2.4 Miura et al. Data 30 3.3 Estimated Exposure-to-Rash Onset Period and Model Assessments 31 3.3.1 Pre-2022 Data 31 3.3.2 Tarin-Vicente et al. Data 31 3.3.3 Madewell et al. Data 32 3.3.4 Viedma-Martinez et al. Data 32 3.4 Meta-analysis 32 4 Discussion 35 References 40 Appendix 44 Tables & Figures 52 | - |
dc.language.iso | en | - |
dc.title | 比較猴痘在 2022 年之前和 2022 年以後的潛伏期 | zh_TW |
dc.title | Comparison of the incubation period of mpox before and as of 2022 | en |
dc.type | Thesis | - |
dc.date.schoolyear | 111-2 | - |
dc.description.degree | 碩士 | - |
dc.contributor.oralexamcommittee | 林先和;鄭皓元 | zh_TW |
dc.contributor.oralexamcommittee | Hsien-Ho Lin;Cheng Hao-Yuan | en |
dc.subject.keyword | 猴痘,Mpox,貝葉斯統計學,潛伏期,隔離, | zh_TW |
dc.subject.keyword | monkeypox,mpox,Bayesian statistics,incubation period,quarantine,rash, | en |
dc.relation.page | 61 | - |
dc.identifier.doi | 10.6342/NTU202301209 | - |
dc.rights.note | 同意授權(全球公開) | - |
dc.date.accepted | 2023-06-29 | - |
dc.contributor.author-college | 公共衛生學院 | - |
dc.contributor.author-dept | 全球衛生學位學程 | - |
顯示於系所單位: | 全球衛生學位學程 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-111-2.pdf | 1.65 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。